Adcetris structure?

What is the molecular structure of Adcetris?

Adcetris, also known as Brentuximab Vedotin, is a monoclonal antibody-drug conjugate (mAb-ADC) used to treat Hodgkin lymphoma and certain types of non-Hodgkin lymphoma [1]. It consists of a monoclonal antibody, brentuximab, linked to a microtubule inhibitor, vedotin.

Brentuximab: Targeting CD30

Brentuximab is a monoclonal antibody that binds to CD30, a protein expressed on the surface of Hodgkin lymphoma cells and some other lymphomas. This binding enables the targeting of cancer cells while sparing healthy cells.

Vedotin: Cell-killing payload

The vedotin component is a microtubule inhibitor that disrupts the assembly of microtubules in cancer cells, leading to cell death. This payload is designed to be selectively activated within cancer cells after brentuximab has bound to CD30.

Why is the structure of Adcetris important?

Understanding the structure of Adcetris is crucial for its mechanism of action, as well as for the development of resistance and for its side effects. The unique design of Adcetris allows it to selectively target and kill cancer cells while minimizing harm to healthy tissues.

References

[1] DrugPatentWatch.com: Brentuximab Vedotin (Adcetris) [2] National Cancer Institute: Brentuximab Vedotin (Adcetris)